Canavan disease (CD) is a globally distributed early-onset leukodystrophy.
It is genetic in nature, and results from an autosomally inherited recessiv
e trait that is characterized by loss of the axon's myelin sheath while lea
ving the axons intact, and spongiform degeneration especially in white matt
er. There is also a buildup of N-acetyl-L-aspartate (NAA) in brain, as well
as NAA acidemia and NAA aciduria. The cause of the altered NAA metabolism
has been traced to several mutations in the gene for the production of aspa
rtoacylase, located on chromosome 17, which is the primary enzyme involved
in the catabolic metabolism of NAA. In this review, an attempt is made to c
orrelate the change in NAA metabolism that results from the genetic defects
in CD with the processes involved in the development of the CD syndrome. I
n addition, present efforts to counter the results of the genetic defects i
n this disease are also considered.